Going forward..., page-889

I would be disappointed with the short term SP dip if Fuji don't exercise, but i wouldn't be disappointed with the opportunity to sell our one of a kind technology to someone who is willing to pay more than $3m for it. Especially now it has been proven to be safe and effective (more effective than some already approved commercial treatments?) in a clinical trial. I would not be surprised if there are a few companies with their finger on the trigger in case Fuji do not exercise. 
I have been of the opinion that we are lacking further partners for different indications because Fuji currently seems to have an option to trump any competitor during this period. 
At the moment i'm leaning towards an exercise of the option by Fuji but no TO. I know this may cause some consternation among some, but it will give us a chance to get new partners on board and increase the aggregate value of the company through multiple trials.